478
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis

, , , , , & show all
Pages 243-251 | Received 11 Oct 2017, Accepted 22 Nov 2017, Published online: 07 Dec 2017

References

  • Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48:225–229.
  • Yahagi N, Fujishiro M, Kakushima N, et al. Merits and demerits of endoscopic submucosal dissection using a flex-knife. Stomach Intest. 2004;39:39–43.
  • Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005;3(7 suppl 1):S67–S70.
  • Toyonaga T, Nishino E, Man IM, et al. Principles of quality controlled endoscopic submucosal dissection with appropriate dissection level and high quality resected specimen. Clin Endosc. 2012;45:362–374.
  • Kakushima N, Fujishiro M, Kodashima S, et al. Histopathologic characteristics of gastric ulcers created by endoscopic submucosal dissection. Endoscopy. 2006;38:412–415.
  • Lee SH, Lee CK, Chung IK, et al. Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers: a retrospective analysis and prospective validation study. Dig Dis Sci. 2012;57:429–434.
  • Oda I, Gotoda T, Hamanaka H, et al. Endoscopic submucosal dissection of early gastric cancer: technical feasibility, operation time, and complications from a large consecutive series. Dig Endosc. 2005;17:54–58.
  • Takizawa K, Oda I, Gotoda T, et al. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection-an analysis of risk factors. Endoscopy. 2008; 40:179–183.
  • Uedo N, Takeuchi Y, Yamada T, et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007;102:1610–1616.
  • Park YM, Cho E, Kang HY, et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011;25:2666–2677.
  • Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–648.
  • Fujiwara S, Morita Y, Toyonaga T, et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol. 2011;46:595–602.
  • Lim JH, Kim SG, Choi J, et al. Risk factors of delayed ulcer healing after gastric endoscopic submucosal dissection. Surg Endosc. 2015;29:3666–3673.
  • Niimi K, Fujishiro M, Goto O, et al. Prospective single-arm trial of two-week rabeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection. Dig Endosc. 2012; 24:110–116.
  • Kobayashi M, Takeuchi M, Hashimoto S, et al. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci. 2012;57:119–126.
  • Horikawa Y, Mimori N, Mizutamari H, et al. Proper muscle layer damage affects ulcer healing after gastric endoscopic submucosal dissection. Dig Endosc. 2015;27:747–753.
  • Kakushima N, Fujishiro M, Yahagi N, et al. Helicobactor pylori status and the extent of gastric atrophy do not affect ulcer healing after endoscopic submucosal dissection. J Gastroenterol Hepatol. 2006;21:1586–1589.
  • Kakushima N, Yahagi N, Fujishiro M, et al. The healing process of artificial ulcers after endoscopic submucosal dissection. Dig Endosc. 2004;16:327–331.
  • Ross ME, Kreider AR, Huang YS, et al. Propensity score methods for analyzing observational data like randomized experiments: challenges and solutions for rare outcomes and exposures. Am J Epidemiol. 2015;181:989–995.
  • Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000; 3:219–225.
  • Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.
  • Horikawa Y, Toyonaga T, Mizutamari H, et al. Feasibility of knife-coagulated cut in gastric endoscopic submucosal dissection: a case-control study. Digestion. 2016; 94:192–198.
  • Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma 3rd English Edition. Gastric Cancer. 2011;14:101–112.
  • Tarnawski AS, Ahluwalia A, Jones MK. Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging. J Gastroenterol Hepatol. 2014;29:112–123.
  • Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci. 2005;50:S24–S33.
  • Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–956.
  • Sakurai K, Suda H, Ido Y, et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. Wjg. 2017;23:668–675.
  • Shimatani T, Inoue M, Kuroiwa T. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006;79:144–152.
  • Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–730.
  • Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449–1461.
  • Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048–1059.
  • Kagawa T, Iwamuro M, Ishikawa S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther. 2016;44:583–591.
  • Maruoka D, Arai M, Kasamatsu S, et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: a propensity score-matching analysis. Dig Endosc. 2016;29:57–64.
  • Takahashi K, Sato Y, Kohisa J, et al. Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. Wjge. 2016;8:716–722.
  • Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc. 2017;29:576–583.
  • Miyoshi A, Aoki T, Matsuo Y, et al. The effects of Omeprazole on upper gastrointestinal bleeding: pilot study (Japanese literature). Jpn Pharmacol Ther. 1995;23:49–59.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.